Alicia M. Fry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alicia M. Fry has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
Sonja J. Olsen
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
6 shared publicationsLyn Finelli
Influenza Division, National Center for Immunizations and Respiratory Diseases
5 shared publicationsJoseph Bresee
Influenza Division, National Centers for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, United States
4 shared publicationsLarisa Gubareva
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
3 shared publicationsLarry J. Anderson
Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
3 shared publicationsMalinee Chittaganpitch
Thailand National Institute of Health, Ministry of Public Health, Nonthaburi, Thailand
3 shared publications
Latest Publications
- 1 April 2018
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 141 (4) , e20172918
Influenza-Associated Pediatric Deaths in the United States, 2010–2016
BACKGROUND: Influenza-associated pediatric deaths became a notifiable condition in the United States in 2004. METHODS: We analyzed deaths in children aged n = 149 of 477) of children aged ≥6 months had received any influenza vaccination. Overall, 65% (n = 410 of 628) of children died within 7 days after symptom onset. Half of the children (n = 327 of 654) had no preexisting medical conditions. Compared with children with preexisting medical conditions, children with none were younger (median: 5 vs 8 years old), less vaccinated (27% vs 36%), more likely to die before hospital admission (77% vs 48%), and had a shorter illness duration (4 vs 7 days; P < .05 for all). CONCLUSIONS: Each year, influenza-associated pediatric deaths are reported. Young children have the highest death rates, especially infants aged <6 months. Increasing vaccination among children, pregnant women, and caregivers of infants may reduce influenza-associated pediatric deaths.
- 1 April 2018
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 141 (4) , e20172918
Influenza-Associated Pediatric Deaths in the United States, 2010–2016
BACKGROUND: Influenza-associated pediatric deaths became a notifiable condition in the United States in 2004. METHODS: We analyzed deaths in children aged n = 149 of 477) of children aged ≥6 months had received any influenza vaccination. Overall, 65% (n = 410 of 628) of children died within 7 days after symptom onset. Half of the children (n = 327 of 654) had no preexisting medical conditions. Compared with children with preexisting medical conditions, children with none were younger (median: 5 vs 8 years old), less vaccinated (27% vs 36%), more likely to die before hospital admission (77% vs 48%), and had a shorter illness duration (4 vs 7 days; P < .05 for all). CONCLUSIONS: Each year, influenza-associated pediatric deaths are reported. Young children have the highest death rates, especially infants aged <6 months. Increasing vaccination among children, pregnant women, and caregivers of infants may reduce influenza-associated pediatric deaths.
- Open Access
- 16 December 2017
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 17 (1) , 208
Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults
Pneumonia poses a significant burden to the U.S. health-care system. However, there are few data focusing on severe pneumonia, particularly cases of pneumonia associated with specialized care in intensive care units (ICU). We used administrative and electronic medical record data from six integrated health care systems to estimate rates of pneumonia hospitalizations with ICU admissions among adults during 2006 through 2010. Pneumonia hospitalization was defined as either a primary discharge diagnosis of pneumonia or a primary discharge diagnosis of sepsis or respiratory failure with a secondary diagnosis of pneumonia in administrative data. ICU admissions were collected from internal electronic medical records from each system. Comorbidities were identified by ICD-9-CM codes coded during the current pneumonia hospitalization, as well as during medical visits that occurred during the year prior to the date of admission. We identified 119,537 adult hospitalizations meeting our definition for pneumonia. Approximately 19% of adult pneumonia hospitalizations had an ICU admission. The rate of pneumonia hospitalizations requiring ICU admission during the study period was 76 per 100,000 population/year; rates increased for each age-group with the highest rates among adults aged ≥85 years. Having a co-morbidity approximately doubled the risk of ICU admission in all age-groups. Our study indicates a significant burden of pneumonia hospitalizations with an ICU admission among adults in our cohort during 2006 through 2010, especially older age-groups and persons with underlying medical conditions. These findings reinforce current strategies aimed to prevent pneumonia among adults.
- 16 December 2017
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 17 (1) , 208
Open AccessRates and risk factors associated with hospitalization for pneumonia with ICU admission among adults
Pneumonia poses a significant burden to the U.S. health-care system. However, there are few data focusing on severe pneumonia, particularly cases of pneumonia associated with specialized care in intensive care units (ICU). We used administrative and electronic medical record data from six integrated health care systems to estimate rates of pneumonia hospitalizations with ICU admissions among adults during 2006 through 2010. Pneumonia hospitalization was defined as either a primary discharge diagnosis of pneumonia or a primary discharge diagnosis of sepsis or respiratory failure with a secondary diagnosis of pneumonia in administrative data. ICU admissions were collected from internal electronic medical records from each system. Comorbidities were identified by ICD-9-CM codes coded during the current pneumonia hospitalization, as well as during medical visits that occurred during the year prior to the date of admission. We identified 119,537 adult hospitalizations meeting our definition for pneumonia. Approximately 19% of adult pneumonia hospitalizations had an ICU admission. The rate of pneumonia hospitalizations requiring ICU admission during the study period was 76 per 100,000 population/year; rates increased for each age-group with the highest rates among adults aged ≥85 years. Having a co-morbidity approximately doubled the risk of ICU admission in all age-groups. Our study indicates a significant burden of pneumonia hospitalizations with an ICU admission among adults in our cohort during 2006 through 2010, especially older age-groups and persons with underlying medical conditions. These findings reinforce current strategies aimed to prevent pneumonia among adults.
- 6 October 2016
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 21 (40)
Letter to the editor: Regarding the editorial by Penttinen and Friede
- 6 October 2016
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 21 (40)
Letter to the editor: Regarding the editorial by Penttinen and Friede
- Open Access
- 29 January 2016
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 10 (2) , 86-90
Survey of influenza and other respiratory viruses diagnostic testing in US hospitals, 2012–2013
Background: Little is known about laboratory capacity to routinely diagnose influenza and other respiratory viruses at clinical laboratories and hospitals.Aims: We sought to assess diagnostic practices for influenza and other respiratory virus in a survey of hospitals and laboratories participating in the US Influenza Hospitalization Surveillance Network in 2012–2013.Materials and Methods: All hospitals and their associated laboratories participating in the Influenza Hospitalization Surveillance Network (FluSurv‐NET) were included in this evaluation. The network covers more than 80 counties in 15 states, CA, CO, CT, GA, MD, MN, NM, NY, OR, TN, IA, MI, OH, RI, and UT, with a catchment population of ~28 million people. We administered a standardized questionnaire to key personnel, including infection control practitioners and laboratory departments, at each hospital through telephone interviews.Results: Of the 240 participating laboratories, 67% relied only on commercially available rapid influenza diagnostic tests to diagnose influenza. Few reported the availability of molecular diagnostic assays for detection of influenza (26%) and other viral pathogens (≤20%) in hospitals and commercial laboratories.Conclusion: Reliance on insensitive assays to detect influenza may detract from optimal clinical management of influenza infections in hospitals.
- 29 January 2016
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 10 (2) , 86-90
Open AccessSurvey of influenza and other respiratory viruses diagnostic testing in US hospitals, 2012–2013
Background: Little is known about laboratory capacity to routinely diagnose influenza and other respiratory viruses at clinical laboratories and hospitals.Aims: We sought to assess diagnostic practices for influenza and other respiratory virus in a survey of hospitals and laboratories participating in the US Influenza Hospitalization Surveillance Network in 2012–2013.Materials and Methods: All hospitals and their associated laboratories participating in the Influenza Hospitalization Surveillance Network (FluSurv‐NET) were included in this evaluation. The network covers more than 80 counties in 15 states, CA, CO, CT, GA, MD, MN, NM, NY, OR, TN, IA, MI, OH, RI, and UT, with a catchment population of ~28 million people. We administered a standardized questionnaire to key personnel, including infection control practitioners and laboratory departments, at each hospital through telephone interviews.Results: Of the 240 participating laboratories, 67% relied only on commercially available rapid influenza diagnostic tests to diagnose influenza. Few reported the availability of molecular diagnostic assays for detection of influenza (26%) and other viral pathogens (≤20%) in hospitals and commercial laboratories.Conclusion: Reliance on insensitive assays to detect influenza may detract from optimal clinical management of influenza infections in hospitals.
- Open Access
- 3 October 2014
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 211 (7) , 1033-1035
Advancing Treatment Options for Influenza: Challenges With the Human Influenza Challenge
(See the major article by Ramos et al on pages 1038–44.)
- 3 October 2014
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 211 (7) , 1033-1035
Open AccessAdvancing Treatment Options for Influenza: Challenges With the Human Influenza Challenge
(See the major article by Ramos et al on pages 1038–44.)
- 1 September 2014
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 134 (3) , 546-554
Hospitalizations for Severe Lower Respiratory Tract Infections
BACKGROUND: Hospitalization for lower respiratory tract infections (LRTIs) among children have been well characterized. We characterized hospitalizations for severe LRTI among children. METHODS: We analyzed claims data from commercial and Medicaid insurance enrollees (MarketScan) ages 0 to 18 years from 2007 to 2011. LRTI hospitalizations were identified by the first 2 listed International Classification of Diseases, Ninth Revision discharge codes; those with ICU admission and/or receiving mechanical ventilation were defined as severe LRTI. Underlying conditions were determined from out- and inpatient discharge codes in the preceding year. We report insurance specific and combined rates that used both commercial and Medicaid rates and adjusted for age and insurance status. RESULTS: During 2007–2011, we identified 16 797 and 12 053 severe LRTI hospitalizations among commercial and Medicaid enrollees, respectively. The rates of severe LRTI hospitalizations per 100 000 person-years were highest in children aged <1 year (commercial: 244; Medicaid: 372, respectively), and decreased with age. Among commercial enrollees, ≥1 condition increased the risk for severe LRTI (1 condition: adjusted relative risk, 2.68; 95% confidence interval, 2.58–2.78; 3 conditions: adjusted relative risk, 4.85; 95% confidence interval, 4.65–5.07) compared with children with no medical conditions. Using commercial/Medicaid combined rates, an estimated 31 289 hospitalizations for severe LRTI occurred each year in children in the United States. CONCLUSIONS: Among children, the burden of hospitalization for severe LRTI is greatest among children aged <1 year. Children with underlying medical conditions are at greatest risk for severe LRTI hospitalization.
- 1 September 2014
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 134 (3) , 546-554
Hospitalizations for Severe Lower Respiratory Tract Infections
BACKGROUND: Hospitalization for lower respiratory tract infections (LRTIs) among children have been well characterized. We characterized hospitalizations for severe LRTI among children. METHODS: We analyzed claims data from commercial and Medicaid insurance enrollees (MarketScan) ages 0 to 18 years from 2007 to 2011. LRTI hospitalizations were identified by the first 2 listed International Classification of Diseases, Ninth Revision discharge codes; those with ICU admission and/or receiving mechanical ventilation were defined as severe LRTI. Underlying conditions were determined from out- and inpatient discharge codes in the preceding year. We report insurance specific and combined rates that used both commercial and Medicaid rates and adjusted for age and insurance status. RESULTS: During 2007–2011, we identified 16 797 and 12 053 severe LRTI hospitalizations among commercial and Medicaid enrollees, respectively. The rates of severe LRTI hospitalizations per 100 000 person-years were highest in children aged <1 year (commercial: 244; Medicaid: 372, respectively), and decreased with age. Among commercial enrollees, ≥1 condition increased the risk for severe LRTI (1 condition: adjusted relative risk, 2.68; 95% confidence interval, 2.58–2.78; 3 conditions: adjusted relative risk, 4.85; 95% confidence interval, 4.65–5.07) compared with children with no medical conditions. Using commercial/Medicaid combined rates, an estimated 31 289 hospitalizations for severe LRTI occurred each year in children in the United States. CONCLUSIONS: Among children, the burden of hospitalization for severe LRTI is greatest among children aged <1 year. Children with underlying medical conditions are at greatest risk for severe LRTI hospitalization.
- Open Access
- 6 May 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 59 (3) , 406-409
Modeling the Effect of Different Vaccine Effectiveness Estimates on the Number of Vaccine-Prevented Influenza-Associated Hospitalizations in Older Adults
We compared influenza vaccine–prevented hospitalizations in adults aged ≥65 years for a range of hypothetical effectiveness estimates. During 2012–2013, a vaccine with 10% effectiveness (66% coverage) would have averted approximately 13 000 hospitalizations, and a vaccine with 40% effectiveness would have averted approximately 60 000 hospitalizations. Annual vaccination is merited in this vulnerable population.
- 6 May 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 59 (3) , 406-409
Open AccessModeling the Effect of Different Vaccine Effectiveness Estimates on the Number of Vaccine-Prevented Influenza-Associated Hospitalizations in Older Adults
We compared influenza vaccine–prevented hospitalizations in adults aged ≥65 years for a range of hypothetical effectiveness estimates. During 2012–2013, a vaccine with 10% effectiveness (66% coverage) would have averted approximately 13 000 hospitalizations, and a vaccine with 40% effectiveness would have averted approximately 60 000 hospitalizations. Annual vaccination is merited in this vulnerable population.
- 1 May 2014
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 2 (5) , 346-8
Effectiveness of neuraminidase inhibitors for severe influenza.
- 1 May 2014
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 2 (5) , 346-8
Effectiveness of neuraminidase inhibitors for severe influenza.